Development of New Genome Editing Tools for the Treatment of Hyperlipidemia

Abstract

Hyperlipidemia is a medical condition characterized by high levels of lipids in the blood. It is often associated with an increased risk of cardiovascular diseases such as heart attacks and strokes. Traditional treatment approaches for hyperlipidemia involve lifestyle modifications, dietary changes, and the use of medications like statins. Recent advancements in genome editing technologies, including CRISPR-Cas9, have opened up new possibilities for the treatment of this condition. This review provides a general overview of the main target genes involved in lipid metabolism and highlights the progress made during recent years towards the development of new treatments for dyslipidemia.

Landscape of NRXN1 Gene Variants in Phenotypic Manifestations of Autism Spectrum Disorder: A Systematic Review

“…It is well-known that treating genetic disorders is a complex challenge, typically addressed by a comprehensive, multi-faceted team employing various therapeutic modalities. One of the emerging approaches in treating genetic disorders involves gene editing [100][101][102]. This technique uses a biological system, such as CRISPR/Cas9, to precisely excise a specific gene segment and employ a biological vector to insert a desired sequence [103][104][105][106].…”

Advancements In Pharmacotherapy for Hyperlipidemia: A Comprehensive Review of Recent Drug Innovations and Clinical Outcomes

“…121 Strategies such as CRISPR/Cas9-mediated gene editing 122 and adeno-associated virus (AAV) vector delivery 123 hold promise for rectifying genetic mutations associated with FH and other monogenic lipid disorders. 124 Investigation into antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) as potential therapeutic agents for lowering LDL cholesterol levels by targeting specific genes involved in cholesterol metabolism, such as PCSK9 and apoB, signifies a novel approach to LDL cholesterol reduction. 125 RNA-based therapies offer a potential alternative treatment avenue for patients who are intolerant to statins or other lipid-lowering drugs.…”